Riluzole

产品编号: DC8985
Riluzole
结构式
1744-22-5
此产品仅供科研所需,我们不出售给病人
​我们将匹配市场上最好的价格给您
Email:order@dcbio.cn
免费咨询电话:4008862077
我们的合作伙伴:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
中国地区超过5000个高品质化合物库存
应用领域
Riluzole is a glutamate antagonist used as an anticonvulsant and to prolong the survival of patients with amyotrophic lateral sclerosis.
Cas No.: 1744-22-5
名称:
别名:
SMILES: FC(F)(F)OC1C=CC2N=C(N)SC=2C=1
分子式: C8H5F3N2Os
分子量: 234.2
纯度:
保存条件: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description:
In Vivo:
In Vitro:
References: Riluzole is a glutamate antagonist used as an anticonvulsant and to prolong the survival of patients with amyotrophic lateral sclerosis.Riluzole inhibits the release of glutamic acid from cultured neurons, and from brain slices. These effects may be partly due to inactivation of voltage-dependent sodium channels on glutamatergic nerve terminals, as well as activation of a G-protein-dependent signal transduction process. Electrophysiologic experiments performed on isolated excitatory amino acid receptors expressed in the Xenopus oocyte have revealed that Riluzole inhibits currents evoked by N-methyl-D-aspartate (NMDA) (IC50 = 18 μM) and kainic acid (IC50 = 167 μM). Riluzole has been shown to stabilize inactivated sodium channels in frog sciatic nerve, in rat cerebellar granule cells, and on recombinant rat sodium channels expressed in Xenopus oocytes (Ki = 0.2 μM). Riluzole can easily cross the blood-brain barrier. Riluzole has neuroprotective, anticonvulsant, and sedative properties in vivo. In a rodent model of transient global cerebral ischemia, a complete suppression of the ischemia-evoked surge in glutamic acid release has been observed by Riluzole treatment (8 mg/kg i.p.).
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
TITLE DOWNLOAD
MSDS_3522_DC8985_1744-22-5
COA
LOT NO. DOWNLOAD
产品编号 产品名称 应用领域
DCAPI1560 Sitagliptin phosphate Sitagliptin phosphate, an orally active agent, potently inhibits CD26 (DPP-4) with an IC50 of 19 nM. Sitagliptin performs a direct, novel action in order to stimulate GLP-1 secretion by the intestinal L cell through a DPP-4-independent, protein kinase A-
DCAPI1552 streptomycin streptomycin
DCAPI1520 S-adenosyl-L-methionine S-adenosyl-L-methionine
DCAPI1436 Milbemycin oxime Milbemycin oxime is a semi-synthetic macrocyclic lactone prepared by the oxidation and oximation of a mixture of two natural products, milbemycin A3 and A4 (in ~70: 30 ratio). Moxidectin oxime, marketed as Interceptor, is used therapeutically for the prev
DCAPI1425 Anastrozole Anastrozole is known to inhibit the CYP19 enzyme (aromatase, IC50 = 15 nM) that converts androgens to estrogens. Anastrozole has been seen to reversibly bind to the CYP19 enzyme through competitive inhibition.
DCAPI1398 Disulfiram (Antabuse) Disulfiram (Antabuse)
DCAPI1393 Nedaplatin (Aqupla) Nedaplatin (Aqupla) is a derivative of cisplatin for inhibition of tumor colony forming units with IC50 of 28.5 μg/mL.
DCAPI1391 Ranolazine (Ranexa) Ranolazine (Ranexa)
DCAPI1374 Cyclovirobuxin D(Bebuxine) Cyclovirobuxin D(Bebuxine)
DCAPI1231 Salinomycin (Procoxacin) For the detailed information of Salinomycin (Procoxacin), the solubility of Salinomycin (Procoxacin) in water, the solubility of Salinomycin (Procoxacin) in DMSO, the solubility of Salinomycin (Procoxacin) in PBS buffer, the animal experiment(test) (test)